Newron Pharmaceuticals

Overview
Price performance
Financials
Research
Sector insights
Thematics

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase II/III trial programme targeting schizophrenia.

Xadago is marketed as an add-on to levodopa therapy in PD. It is currently sold in Europe, Japan, the United States and other territories. Generic manufacturers have notified the FDA of their intention to file generic Xadago products. Newron is contesting these filings. Xadago is currently patent protected until at least 2027.

Latest Insights

Healthcare |
Flash note

26.06.24

Newron Pharmaceuticals — Evenamide road to registration and beyond

Healthcare |
Flash note

14.05.24

Newron Pharmaceuticals — Evenamide potential for treatment of schizophrenia

Healthcare |
Flash note

01.05.24

Newron Pharmaceuticals — Evenamide notches up another win (study 008A)

Healthcare |
Update

20.03.24

Newron Pharmaceuticals — Evenamide set for a pivotal year

Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Analyst, Healthcare

Key Management

Marco Caremi

Executive VP of Business Development
Stefan Weber

CEO

Balance Sheet

Forecast net cash (€m)

29.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(17.2)	5.3	27.9
Relative	(17.8)	2.4	18.6
52 week high/low	CHF11.0/CHF4.2

Financials

Newron is developing evenamide as an add-on therapy for poorly managed and treatment-resistant schizophrenia (TRS). In April/May 2024, Newron shared positive results from a Phase II/III trial (study 008A) in patients with schizophrenia who are taking antipsychotics but not classified as having TRS (primary and key secondary endpoints met). In January 2024, positive final results (12-month data for the full patient cohort) were announced for a Phase II trial (study 014/015) in TRS patients. Over 70% of patients experienced a clinically meaningful reduction in disease severity and 25% achieved remission. With these encouraging results in hand, Newron now intends to begin a potentially pivotal, multinational Phase III schizophrenia programme (expected to start in 2024). In its FY23 results, Newron recorded total revenue of €9.1m (up 48.6% y-o-y) for the period, primarily derived from Xadago-related royalty income.